Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib in Colorectal Cancer and Other Solid Tumors
NCT05731947Phase 2Terminated
- Sponsor
- Syndax Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of revumenib in colorectal cancer (CRC) and solid tumor (4 arms), sponsored by Syndax Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities, Treatment-emergent Adverse Events up to 2.2 years and 3 more. Started Apr 2023; status: terminated.
02
Drugs
revumenib
03
Conditions
colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT05731947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731947.